8-K: HCW Biologics Announces Full Exercise of Pre-Funded Warrants by Armistice Capital

HCW Biologics Inc. reported the full exercise of all outstanding pre-funded warrants by Armistice Capital Master Fund Ltd., completing a previously announced securities purchase agreement.

Summary

• HCW Biologics Inc. announced the full exercise of pre-funded warrants by Armistice Capital Master Fund Ltd.
• The warrants were granted as part of a Securities Purchase Agreement entered into on May 13, 2025.
• The initial grant was for up to 513,140 shares of common stock with a par value of $0.0001 per share, exercisable at $0.0001 per share.
• Armistice Capital previously exercised warrants for an aggregate of 459,140 shares.
• On June 18, 2025, Armistice Capital exercised the remaining 54,000 shares of common stock.
• Following this exercise, all pre-funded warrants have been fully exercised, with none left outstanding.

Sentiment

Score: 6

Explanation: The filing reports the successful and complete exercise of pre-funded warrants, which is a neutral to slightly positive event as it finalizes a financing transaction and removes uncertainty regarding future warrant exercises. It does not introduce new positive or negative operational news.

Positives

• The completion of the pre-funded warrant exercise eliminates uncertainty regarding potential future dilution from these specific warrants.
• The exercise price of $0.0001 per share indicates the warrants were deeply in-the-money, suggesting the original capital raise was beneficial for the company.

Future Outlook

The filing indicates the completion of the pre-funded warrant exercise, with no further outstanding warrants of this type, concluding this specific financing event.

Management Comments

• Hing C. Wong, Founder and Chief Executive Officer, signed the report on behalf of HCW Biologics Inc.

Industry Context

This filing details a specific financing transaction for HCW Biologics, a biotechnology company. Such warrant exercises are common mechanisms for investors to convert their investment instruments into common equity, often following initial capital raises in the biotech sector to fund research and development or operational expenses.

Related Party Transactions

• The transaction involves Armistice Capital Master Fund Ltd., a significant investor that entered into a Securities Purchase Agreement with HCW Biologics Inc.

Stakeholder Impact

• Shareholders: The exercise of warrants results in the issuance of common stock, potentially increasing the number of outstanding shares and leading to dilution for existing shareholders, though this was anticipated from the initial agreement.
• Armistice Capital Master Fund Ltd.: The fund has converted its pre-funded warrants into common stock, solidifying its equity position in the company.

Key Dates

Keywords

HCW Biologics, Armistice Capital, Pre-Funded Warrants, Common Stock, SEC Filing, 8-K, Securities Purchase Agreement, Warrant Exercise, Biologics